2026-07-18T13:53:18Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1380922026-07-08T00:15:13Zcom_20.500.14352_14col_20.500.14352_15

Zhang, Qian González Granado, Luis Ignacio Casanova, Jean Laurent 2026-07-07T08:01:05Z 2026-07-07T08:01:05Z 2022-11-07 Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022 Nov 7;219(11):e20220514. doi: 10.1084/jem.20220514. PMID: 36112363; PMCID: PMC9485705. 0022-1007 10.1084/jem.20220514 https://hdl.handle.net/20.500.14352/138092 1540-9538 https://doi.org/10.1084/jem.20220514 36112363 https://rupress.org/jem/article/219/11/e20220514/213469/Autoantibodies-against-type-I-IFNs-in-patients https://pubmed.ncbi.nlm.nih.gov/36112363/ Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old. eng http://creativecommons.org/licenses/by/4.0/ open access Attribution 4.0 International Autoantibodies against type I IFNs in patients with critical influenza pneumonia. journal article